Jacobs Levy Equity Management Inc. Has $1.86 Million Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Jacobs Levy Equity Management Inc. lowered its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 32.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 247,795 shares of the biotechnology company's stock after selling 119,719 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.12% of BioCryst Pharmaceuticals worth $1,863,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of BCRX. Venturi Wealth Management LLC acquired a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at $46,000. R Squared Ltd bought a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at about $48,000. KBC Group NV increased its position in shares of BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock valued at $77,000 after acquiring an additional 4,537 shares during the last quarter. Raymond James Financial Inc. bought a new stake in BioCryst Pharmaceuticals during the fourth quarter worth about $80,000. Finally, Syon Capital LLC bought a new stake in BioCryst Pharmaceuticals during the fourth quarter worth about $99,000. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Stock Performance

NASDAQ:BCRX traded down $0.06 during mid-day trading on Wednesday, hitting $10.28. 571,815 shares of the stock were exchanged, compared to its average volume of 3,005,395. The firm's 50-day simple moving average is $8.22 and its 200 day simple moving average is $7.99. The stock has a market capitalization of $2.15 billion, a price-to-earnings ratio of -16.81 and a beta of 1.08. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $5.92 and a fifty-two week high of $11.11.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to analysts' expectations of $126.64 million. BioCryst Pharmaceuticals's revenue for the quarter was up 40.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.28 EPS. On average, analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Analysts Set New Price Targets

BCRX has been the topic of a number of research analyst reports. Cantor Fitzgerald initiated coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. JPMorgan Chase & Co. upped their price objective on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research note on Tuesday, May 6th. JMP Securities reaffirmed a "market outperform" rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Finally, Barclays boosted their target price on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $16.56.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.